Document |
Document Title |
WO/2008/012385A1 |
The invention relates to phytotoxic halogenated derivatives of benzoxazinones. The aim of the invention relates to the production of novel phytosanitary products that are suitable for agricultural weed control, based on natural chemical ...
|
WO/2008/010897A2 |
Disclosed is a method for preparing a compound of Formula 1 by contacting compound of Formula 2 with R1-NH2 in the presence of a carboxylic acid and a method for preparing a compound of Formula 2 by contacting a compound of Formula 4 wit...
|
WO/2008/007780A1 |
Disclosed is a pentadienamide derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof or the like. (I) wherein R1 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic h...
|
WO/2008/005954A2 |
The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. In general aspects, compounds of the present invention are tyrphostin-like in structure. Compounds of the present invention, in c...
|
WO/2007/148775A1 |
Disclosed is an agent for treatment of hypertension. Specifically disclosed is a pharmaceutical product containing a compound represented by the following general formula (I). [chemical formula 1] (I) (In the formula, R1 represents H, an...
|
WO/2007/138998A1 |
Disclosed is a pharmaceutical composition which is effective for the treatment or prevention of a disease associated with uric acid, such as hyperuricemia, tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary cal...
|
WO/2007/139002A1 |
It is intended to provide a method for producing an excellent compound effective in the treatment, prevention or the like of pathological conditions associated with uric acid such as hyperuricemia, tophus, acute gouty arthritis, chronic ...
|
WO/2007/136790A2 |
Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.
|
WO/2007/133800A2 |
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 or TLR7 receptors, Trif or of IL-10 or IL-12 inhibits ocular angiogenesis. Fur...
|
WO/2007/125952A1 |
Disclosed is a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, or a solvate of any of them. (I) In the formula, R1 represents an optionally substituted lower alkyl group; Y represents -S(O)n- (w...
|
WO/2007/125398A2 |
This invention provides the compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Q is CH2 or the like; Z1 is CRa or the like; Z2 is CRb or the like; R1 and R2 are each independently hydrogen or the like, Ra, R...
|
WO/2007/122277A1 |
4-acyloyloxy-2H-1,4-benzoxazin-3-(4H)one derivatives with phytotoxic activity. The invention belongs to the field of chemical compounds applicable to the control of pests in agriculture. The existence of a wide variety of pests in agricu...
|
WO/2007/123516A1 |
The invention is directed to compounds of Formula II: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein t...
|
WO/2007/117557A2 |
Described are diaminopropanols of which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with elevated. levels of renin activity or in the treatment of a...
|
WO/2007/117560A2 |
Described are compounds which are orally active and bind to renin to inhibit its activity. They are useful in the treatment or amelioration of diseases associated with renin activity. Also described are methods of use of these compounds ...
|
WO/2007/117482A2 |
Disclosed are compounds according to Formula (I): wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated...
|
WO/2007/117559A2 |
Described are compounds of the formula ( I ) which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also ...
|
WO/2007/114213A1 |
[PROBLEMS] To provide a compound capable of inhibiting the production of a prostaglandin or leukotriene. [MEANS FOR SOLVING PROBLEMS] Disclosed is a compound represented by the general formula (I) or a salt thereof: (I) wherein (a) repre...
|
WO/2007/113218A1 |
The present invention discloses a new process for the preparation of 3-[4-(l,l- dimethyl-propyl)-phenyl]-2-methyl-propionaldehyde and for the preparation of c/5'-4-{3-[4- (1,1 -dimethyl-propyl)-phenyl] -2-methyl-propyl } -2,6-dimethyl-mo...
|
WO/2007/109288A2 |
Enantiomerically pure R-etifoxine and pharmaceutically acceptable salts, solvates, hydrates or prodrugs thereof are provided. Also provided are pharmaceutical compositions comprising the compounds and methods of treating disorders associ...
|
WO/2007/109289A1 |
Enantiomerically pure S-etifoxine and pharmaceutically acceptable salts, solvates, hydrates or prodrugs thereof are provided. Also provided are pharmaceutical compositions comprising the compounds and methods of treating disorders associ...
|
WO/2007/104582A1 |
The invention relates to poly-substituted tetrahydronaphtalene derivatives of formula (Ia) and to methods for the production and the use thereof as anti-inflammatory agents.
|
WO/2007/105650A1 |
Stable 4-hydroxyisoleucine derivatives; and a process for producing the derivatives. The compounds of the formula (I) and compounds of the formula (III) are obtained by first protecting 4-hydroxyisoleucine with aminal and an amino protec...
|
WO/2007/099048A2 |
The invention relates to the use of polynuclear phenolic compounds with up to 20 bezene nuclei per molecule, obtained by reaction of a tetrahydrobenzoxazine I, where R1 = a hydrocarbon group and R2, R3, R4and R5 independently = H, OH, or...
|
WO/2007/099828A1 |
Nitrogenous heterocyclic derivatives represented by the general formula (I) which each bind specifically to NR1/NR2B receptor and are useful as NR2B receptor antagonists (particularly analgesic for cancer pain or neuroprotectant); pharma...
|
WO/2007/093507A1 |
The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters the...
|
WO/2007/094022A1 |
It is disclosed a process for the preparation of 2-(4-hydroxy-3-morfolinyl)-2-cycloesenone (BTG-1675A) comprising the steps of: i) reacting N-hydroxymorpholine with cycloesanone in the presence of an oxidation agent thus obtaining an iso...
|
WO/2007/091009A2 |
It comprises a process for the production of delmopinol or a pharmaceutically acceptable salt and/or a solvate thereof, by subjecting the compound of formula (II) where R1 and R2 are the same or different, independently selected from the...
|
WO/2007/092961A2 |
This invention provides compositions which are l,3-oxazinan-2-one compounds of formulae (I) and (II), and oxazolidinone compounds of formula (III): wherein R is a hydrocarbyl group, a heterocyclic group, a hydrocarbyl group having at lea...
|
WO/2007/089034A1 |
The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R1 etc, R1 is a group of t...
|
WO/2007/086504A1 |
Disclosed is an excellent inhibitor of URAT1 activity, which is effective for the treatment of a disease associated with uric acid such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty nephropathy, ur...
|
WO/2007/077228A1 |
The invention relates to a method for preparing a benzoxazine comprising reacting an isatoic anhydride with an acylating compound in the presence of an N-alkyl imidazole, to a method for preparing a photo-stabilised composition, comprisi...
|
WO/2007/075387A1 |
The present invention relates to heterocyclic compounds that bind to BcI proteins and inhibit BcI function, compositions comprising such compounds, and methods for treating and modulating disorders associated with hyperproliferation, suc...
|
WO/2007/070760A2 |
Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein, R1, R2, A, Y, X, Ar1 and Ar2 have the meanings given in the specification, ...
|
WO/2007/065828A1 |
The present invention relates to compounds of formula (I) wherein A, X, R1, R2 and R3 are as defined herein and pharmaceutically acceptable salts thereof. The invention also relates to methods of using the compounds of formula I and phar...
|
WO/2007/063925A1 |
Disclosed is a novel and excellent therapeutic or prophylactic agent for nociceptive pain, neuropathic pain, cancer pain, headache, bladder dysfunction or the like, which relies on a preventive activity on capsaicin receptor VR1 activati...
|
WO/2007/063950A1 |
A compound represented by the formula (I) or a salt or solvate of the compound; a composition and a kit containing any of these which are for use in the diagnosis of conformation diseases; a medicinal composition containing any of these ...
|
WO/2007/064316A1 |
The invention encompasses a series cyclic bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. ...
|
WO2007037518A9 |
The invention is intended to provide a novel compound which is useful as an antibacterial agent and a manufacturing intermediate thereof and relates to a mutilin derivative represented by the formula (I) which is useful as an antibacteri...
|
WO/2007/057681A1 |
A process for the preparation of delmopinol (3-(4-propylheptyl)-4-morpholinethanol) or a derivative or a pharmaceutically acceptable salt, or a solvate thereof, including an hydrate, comprises reacting oxazolidin [2, 3-c] morpholine and ...
|
WO/2007/058583A2 |
This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impai...
|
WO/2007/057768A2 |
The present invention relates to compounds, pharmaceutical compositions comprising these compounds and methods for treating a condition that is mediated by the modulation of the 11-β-hsd-1 enzyme.
|
WO/2007/054484A1 |
The invention relates to a process for the manufacturing of organic compounds useful for treatment and prevention of respiratory diseases of general Formula (1) and salts thereof, wherein, R1 and R2 each independently mean H, halogen or ...
|
WO/2007/050425A2 |
A compound of formula I,wherein A, X, q, R1, R2a, R2b, R2c, R3a, and R3b are defined herein, useful as liver X receptor modulator.
|
WO/2007/049532A1 |
A BACE 1 inhibitor containing, as an active ingredient, any one of a compound represented by the formula (I): (wherein ring A is an optionally substituted carbocyclic group or optionally substituted heterocyclic group; E is lower alkylen...
|
WO/2007/046247A1 |
A Nile Red type luminescent compound which can emit light of a cardinal red color at a high luminance; and a luminescent element and a molded plastic each employing the compound. The Nile Red type luminescent compound emitting red light ...
|
WO/2007/046022A2 |
The present invention relates to oxazine derivatives, which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in the treatment of CMS disorders, AIDS, asthma, arthritis, bron...
|
WO/2007/044829A2 |
A process for preparing aprepitant.
|
WO/2007/041077A2 |
The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating RXR mediated disorders. More particularly, the compounds of the presen...
|
WO/2007/039736A1 |
The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
|